- Qualitative analysis that evaluates eight markers: BAT25, BAT26, D2S123, D5S346, and D17S250, recommended by the National Cancer Institute (NCI) since 1997 and known as the Bethesda panel; and BAT40, NR21 and NR22, whose sensitivity and informativeness in different tissues has been demonstrated in numerous studies.
- The markers D2S123, D5S346 and D17S250, highly polymorphic in the population, when they do not suffer from instability, are sufficient to evaluate the coincidence of tumor and normal tissue, ensuring the traceability of the samples.
- Amplification range of 90-200 bp.
- Includes a genomic DNA control at the optimal amplification concentration, containing normal alleles for the markers amplified in the kit.
- It complies with the quality requirements specified by ISO 13845 and ISO 14001 in relation to the materials used in its manufacturing process.
- For in vitro diagnostic use.
Description
Detection of microsatellite instability by capillary electrophoresis
Format
48 rxn
Technology
Fragment Analysis
Reference
IMG-314
Compatible equipment
3730xl DNA Analyzer (ThermoFisher Scientific)
MSI OncoKitDx employs oligonucleotides labeled with different fluorophores in an assay that uses standard PCR technique to amplify regions of interest and capillary electrophoresis to detect potential instability of any of the eight microsatellite regions included in this analysis.
- Amount of DNA: 10 ng
- Type of sample: Paraffin or fresh tissue (Tumor), Peripheral blood (Germinal)
- Number of reactions per sample: 1
- Number of targets: 1
- Manual work time: 30 minutes
- Duration of the PCR program: 2 hours
- Compatible thermal cyclers: Any conventional thermal cycler
- Sequencing with polymers compatible with FAMTM , VIC® and NEDTM.
Related kits
MSI OncoKitDx
Fill in the form to request this kit.
Call us at +34 963 212 340Or write to us at info@healthincode.com
